Pancreas Injury, Pancreas; Insulinoma, Pancreatic Adenocarcinoma, Pancreatic Cyst, Pancreatic Cystadenoma, Pancreatic Gastrinoma, Pancreatic Glucagonoma, Pancreatic Neoplasms, Pancreatic Neuroendocrine Tumor, Pancreatic Polypeptide Tumor, Pancreatic Pseudocyst, Pancreatic Teratoma, Pancreatic Tumor, Benign, Pancreatic Vipoma
Conditions
Keywords
Laser Tissue Welding, Pancreatic Sealing, Hemostasis, Pancreatic Tumors, Pancreatic Resection, Pancreatic leakage, LTW
Brief summary
The laser tissue welding device is intended for use in patients requiring sealing of the pancreas after partial pancreatectomy, and including those patients who are fully heparinized or have hemodilutional coagulation failure. The hypothesis is that the laser tissue welding device is safe and effective in sealing the pancreas, thereby decreasing the blood loss (operative and post-operative), and pancreatic juice leakage for patients when the Laser Tissue Welding device is used after pancreatic resection.
Detailed description
UNMET CLINICAL NEED In the United States, pancreatic cancer is the fourth leading cause of cancer-related death in both men and women and will be the second leading case by 2030. Pancreatoduodenectomy (Whipple procedure) and distal partial pancreatectomy is used to treat pancreatic tumors, and these procedures are associated with a high rate of morbidity due to pancreatic fistulae. As per the Surveillance, Epidemiology and End Results (SEER) Program: It is estimated that 41,609 men and women (21,370 men and 21,770 women) will be diagnosed with and 38,460 men and women will die of cancer of the pancreas in 2013. The five-year survival is dismal, 24.1% for localized malignancy, and drops to 6% if there is regional spread. There are 45,220 new cases in 2013 and 38,460 deaths. Distal Pancreatectomy may be indicated for malignant exocrine tumors of the body and tail of pancreas (62%), insulinomas, chronic pancreatitis (12%), pancreatic pseudocysts, non pancreatic tumors (23%) and injury due to trauma. Due to heighten awareness and preventative care, there has been an increase in detection of incidental small pancreatic mass cases due to widespread use of abdominal cross sectional imaging and thus an increase in the amount of pancreatic surgery performed. This is the stage when curative resections may be possible. 1. Surgical removal of the tumor is the only chance of a cure at T1A. 2. All pancreatic tumors at any stage require bulk reduction by a surgical procedure. For patients undergoing distal pancreatectomy, pancreatic fistulas occurred post-operatively in 31% of patients. Over the long-term Kazanjian et al analyzed, 182 patients from 1996-2005 who underwent Pancreatoduodenectomy to treat ductal adenocarcinoma, concluded that the principal factor influencing long-term survival was operative blood loss. Pancreatic fistula is a main cause of postoperative morbidity, and is associated with numerous further complications, such as intra-abdominal abscesses, wound infection, sepsis, electrolyte imbalance, malabsorption, and hemorrhage, and with a dramatically increase in healthcare resource utilization. The current state-of-art pancreatic surgical resections have an unacceptable pancreatic leak rate of 30-50%. This is because there are no FDA cleared or approved sealants or devices found to be safe or effective for sealing this organ. The current standard of care is anything but standard because of the use of off-label devices and sealants. * Endo GIA Staplers: 510 (k) k111825 Cleared on basis of literature review without animal or human safety or efficacy data. * Gore SeamGuard staple/suture reinforcement material 510 (k) k043056 Synthetic bio absorbable glycolide and trimethylene carbonate copolymer. Cleared on basis of in-vivo studies done without performance standards under section 514. * Surgical Sealants: All used off label: None are FDA cleared or approved for pancreatic surgery. These are Floseal, TachoSil, Tisseel, BioGlue, and CoSeal. Jörg Kleeff et al reviewed the factors for surgical failure of distal pancreatectomy in 302 consecutive patients from 1993 to 2006 using four different surgical closures (gut anastomosis, seromuscular patch, suture and stapling device). Although distal pancreatectomy is less moribund as compared to Whipple procedure, morbidity was 32-52%, pancreatic fistulas occurred in 20-33% and mortality in 2% of cases. Pancreatic fistulas contributed significantly to morbidity, sepsis, length of stay and overall costs. Stapler closure of the pancreatic remnant is associated with a significantly higher fistula rate. Laser Tissue Welding is the first combination (laser and biologic) class III surgical device intended to join and seal tissues accurately and instantly. The treatment process uses thermal energy created when a laser excites photosensitive dye molecules, to coagulate the protein albumin which transforms from a liquid to a solid instantly. Laser tissue welding creates a non-compressive, non-ablative sealing of tissues with microscopic thermal damage. This combination of a laser with albumin biologics stops bleeding and fluid leaks in nanoseconds without using sutures, hemostatic clotting factors (platelets/thrombin/fibrin), thermal or cryoablation.
Interventions
DEVICEDistal Pancreatectomy Sealing Using LTW
The device's intended use is to seal the pancreatic surface using a laser to weld human albumin based biomaterials after surgical removal of pancreatic tumors during a partial pancreatectomy.
Sponsors
National Cancer Institute (NCI)
CHI St. Luke's Health, Texas
Laser Tissue Welding, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE
Intervention model description
Open Label Combination Product (Laser + Biologic + Drug) regulated as a device
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Eligible participants will be 18 years and older of both genders. 1. T1a (≤ 4 cm, as measured by the maximal dimension by CT or MRI). Final determination of disease stage is made during the operation by the investigator. All resectable cystic, benign, primary or secondary malignant tumors. 2. Serum creatinine: ≤ 2.5 mg/dL 3. Glomerular filtration rate greater than ≥ 50 ml/min/m2 4. Platelet count ≥ 50,000/mm3 5. Prothrombin time \< 18 seconds 6. PTT not \>1.5 times control (except for therapeutically; anticoagulated nonrelated medical conditions \[e.g., atrial fibrillation\]); 7. Serum albumin levels \> 3g/dL (Normal range 3.5 to 5 g/dL)
Exclusion criteria
1. Age younger than 18 years' old 2. Severe uncorrected hypertension (\> 180 systolic and \>110 diastolic) 3. Uncorrectable coagulopathies (on Plavix, Aspirin or Lovanox) 4. Pregnancy 5. Females who are breast feeding who do not switch the infant to formula prior to surgery 6. Active urinary tract infection 7. T1b (\>4 cm) lesion and above 8. Systemic or local infection. 9. Subject has known allergy or intolerance to iodine or human serum albumin. 10. Recent febrile illness that precludes or delays participation preoperatively. 11. Treatment with another investigational drug or other intervention during the study and follow-up period. 12. Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PRIMARY EFFICACY AS A SEALANT: Intra-operative blood loss | Intra-operative | Operative blood loss is defined by: volume of blood in the suction bottles, volume of blood clots, and weight of surgical towels before and after use. Clinical drop in hemoglobin (1 gm% = 300 ml) without hemodilution. Correlates with intra-operative blood transfusions. Correlates with post-operative blood transfusions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| SECONDARY SAFETY: Post-operative blood loss requiring return to the operating room | 30 days | Secondary hemorrhage or intra-abdominal hematoma requiring surgical evacuation |
| SECONDARY SAFETY: Prolonged post-operative pancreatic leakage | 30 days | Pancreatic juice leakage is measured in drainage bottles (ml/day) following surgery till a drain placed during the operation is removed before patient discharge. Accumulation of fluids around the pancreas will be assessed with U/S and CT scan at the mentioned time points. |
| SECONDARY SAFETY: Surgical space abscess | 30 days | Secondary infection, intra-abdominal abscess formation requiring surgical evacuation |
Other
| Measure | Time frame | Description |
|---|---|---|
| SECONDARY EFFICACY: Total operating time (minutes) | Intra-operative assessment | Duration and Cost Metric |
| SECONDARY EFFICACY: Total hospital stay (Duration and cost Metric ) | 3 months | Duration and Cost Metric |
| SECONDARY EFFICACY: Pancreas clamp time (minutes) | Intra-operative assessment | Duration Metric: Assesses organ ischemia and handling, and will correlate with compromised function (rise in serum Amylase and Lipase) (assesses organ ischemia and will correlate with compromised function) |
| SECONDARY EFFICACY: Laser tissue welding time or time to hemostasis (Duration Metric) | Intra-operative assessment | Duration and Cost Metric |
| SECONDARY EFFICACY: Length of ICU stays (Duration and cost Metric ) | 30 days | Duration and Cost Metric |
Countries
United States
Outcome results
None listed